Abdominal Wall Local Anesthesia to Maximize Postoperative Pain Control After Cesarean Delivery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-07-31

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study has been designed to determine if women undergoing cesarean delivery with spinal anesthesia and routine pain management who also have an additional ultrasound guided transversus abdominis plane (TAP)block using ropivacaine have better pain relief and a better quality of recovery than women who don't have the additional TAP block. Maximizing pain relief using ultrasound guided TAP blocks in addition to neuraxial opioids, NSAIDs, and acetaminophen may improve acute pain outcomes, reduce adverse side effects, and potentially reduce chronic pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transverse Abdominis Plane (TAP) Block After Cesarean Delivery

NCT01170702

Postoperative Pain Pregnancy Obesity

COMPLETED PHASE4

Pain Relief Study of Ultrasound Guided Transverse Abdominis Plane(TAP)Block

NCT01217580

Cesarean Section

WITHDRAWN NA

Efficacy of the Transversus Abdominus Plane (TAP) Block for Post-Cesarean Delivery Analgesia

NCT00573963

Pain

COMPLETED NA

Local Infiltration Analgesia With Ropivacaine Versus Placebo in Caesarean Section

NCT00891540

Pain, Postoperative Postoperative Nausea and Vomiting Cesarean Section

COMPLETED PHASE4

Analgesic Efficacy of Surgeon-administered Transversus Abdominis Plane Blocks for Caesarean Section.

NCT06324942

Cesarean Section Complications Pain, Postoperative

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0.25% Ropivicaine

0.25% ropivicaine (maximum 1.5mg/kg)

Group Type EXPERIMENTAL

Ropivicaine

Intervention Type DRUG

0.25% ropivicaine (maximum 1.5mg/kg)

Placebo

20ml saline

Group Type PLACEBO_COMPARATOR

Saline placebo

Intervention Type DRUG

20ml saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Saline placebo

20ml saline

Intervention Type DRUG

Ropivicaine

0.25% ropivicaine (maximum 1.5mg/kg)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Naropin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-emergent CD with planned spinal anesthesia
* American Society of Anesthesia physical status class I \& II
* Age ≥ 18 years
* Term gestational age (≥ 37 weeks)
* English-speaking

Exclusion Criteria

* Morbid Obesity (BMI³ 45 kg/m2)
* Laboring women
* Emergency CD
* Severe maternal cardiac disease
* Subjects with significant obstetric co-morbidities
* Failed spinal anesthesia
* Patient enrollment in another study involving medication within 30 days of CD
* Any other condition which may impair ability to cooperate with data collection
* Height less than 152 cm (5'0")
* Fetal anomalies or intrauterine fetal death

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes